By Fineline Cube 
Xuanzhu Biopharmaceutical Co., Ltd., a subsidiary of China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange, with China International Capital Corporation (CICC) acting as the sole sponsor. This strategic move aims to secure funding for the advancement of its innovative therapies in gastrointestinal disorders, oncology, and non-alcoholic steatohepatitis (NASH).
Core Products and Development Pipeline
Xuanzhu Biopharmaceutical has three core products that have reached the New Drug Application (NDA) stage. These include KBP-3571, a proton pump inhibitor approved for duodenal ulcer treatment and commercialized since November 2023; XZP-3287, a CDK4/6 inhibitor with two NDAs approved for HR+/HER2- advanced breast cancer and an additional NDA filing accepted in May 2025; and XZP-3621, an ALK inhibitor for ALK+ NSCLC, currently under development as a postoperative adjuvant therapy.
Early-Stage Oncology Assets
The company also boasts four key oncology assets: KM602, KM501, XZP-7797, and XZP-6924, all at Phase I/IND stages. Its NASH pipeline includes XZP-5610 and XZP-6019, which are at Phase I and IND stages, respectively.
IPO Proceeds and Strategic Focus
The net proceeds from the IPO will be dedicated to advancing Xuanzhu Biopharmaceutical’s pipeline development and supporting commercialization efforts. This funding will further solidify the company’s position in the biopharmaceutical sector, enabling it to continue its innovative research and expand its market presence.-Fineline Info & Tech